Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Diadexus, Inc. (OTC: DDXSQ).

Full DD Report for DDXSQ

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-170.0120.0120.0120.012533
2018-12-14N/A0.012N/AN/A0
2018-12-13N/A0.012N/AN/A0
2018-12-120.0120.0120.0120.0127,500
2018-12-110.0120.0120.0120.01218,956

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2125,50028,83288.4434Short
2018-05-3063,829224,79928.3938Cover
2018-05-011,4342,99447.8958Short
2018-03-2120623189.1775Short
2018-03-1575076398.2962Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DDXSQ.


About Diadexus, Inc. (OTC: DDXSQ)

Logo for Diadexus, Inc. (OTC: DDXSQ)

Diadexus, Inc., based in South San Francisco, California, develops and commercializes proprietary cardiovascular diagnostic products addressing unmet needs in cardiovascular disease. The Company s two diagnostic products are the only FDA cleared Lp PLA blood tests to uncover the hidden risk of cardiovascular disease. The PLACA Test ELISA Kit is to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis, the and causes of death, respectively, in the United States. The PLACA Test for Lp PLACA Activity is to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of coronary heart disease in patients with no prior history of cardiovascular events, which represents approximately of coronary heart disease patients. The company also has heart failure biomarkers for development. For more information, please visit the company s website at www.Diadexus.com.

 

Contact Information

 

 

Current Management

  • Lori F. Rafield / CEO
    • Lori Rafield has served as a director of the Company since May , as Chairman of the Board since July , as Interim Chief Executive Officer since January and as Chief Executive Officer since March . Dr. Rafield has years of experience leading, advising, and investing in companies in the life sciences industry. For the last years, Dr. Rafield has served as a consultant to both the biotechnology and device industries working with entrepreneurs to create and finance companies with both institutional investor and strategic partners. She has been involved in creating business plans for new opportunities, restructuring existing companies as well as corporate partnering efforts. From to , Dr. Rafield was Managing Director at Apax Partners formerly Patricof amp Co. Ventures , where she was Head of Healthcare responsible for developing a diversified investment strategy for a million healthcare portfolio within a billion fund. While at Apax, she was predominately focused on the creation of therapeutic product companies from pharmaceutical assets and resources, which lead to investments in Zymogenetics Novo Nordisk , Affymax GSK and Aerovance Bayer . From to , Dr. Rafield was an Investment Principal at Robertson Stephens Early Stage Venture Fund. From to , she was an affiliate at Institutional Venture Partners. Dr. Rafield held scientific research and management positions at Somatix Therapy Corp. from to and at Integrated Genetics, Inc. from to , where she directed molecular biology efforts in the development and expression of recombinant proteins. She received a Ph.D. in in Microbiology at University of Virginia Medical School, and was a Postdoctoral Fellow at Harvard Medical School.
  • Kenneth C Fang, M.D. / Chief Med. Officer
    • Kenneth Fang has served as our Chief Medical Officer since October , . Dr. Fang has extensive corporate experience and a proven track record in biomarker discovery and applications for the development and commercialization of diagnostic products for diverse indications, including cardiovascular disease and inflammation. Prior to joining the Company, Dr. Fang served as the Chief Medical Officer and Vice President, Translational Research and Clinical Development for Integrated Diagnostics, Inc., a molecular diagnostics company, from December through September . From October to November , Dr. Fang was Head of Translational Medicine and Clinical Development for Modus BioMedicine, a startup company developing monoclonal antibodies targeting lymphocytes as therapeutics for immunemediated diseases. From November to September , Dr. Fang was Senior Director, Clinical Development at XDx, Inc., a molecular diagnostics company. Dr. Fang received a B.A. in Biochemistry from the University of Pennsylvania and his M.D. from the University of Pennsylvania School of Medicine. He is BoardCertified in Pulmonary Diseases and Critical Care Medicine. In addition, Dr. Fang was an Assistant Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at the University of California, San Francisco.
  • Xiaoyan Yan Zhao / Corporate Controller
  • Lori F. Rafield / Chairman
    • Lori Rafield has served as a director of the Company since May , as Chairman of the Board since July , as Interim Chief Executive Officer since January and as Chief Executive Officer since March . Dr. Rafield has years of experience leading, advising, and investing in companies in the life sciences industry. For the last years, Dr. Rafield has served as a consultant to both the biotechnology and device industries working with entrepreneurs to create and finance companies with both institutional investor and strategic partners. She has been involved in creating business plans for new opportunities, restructuring existing companies as well as corporate partnering efforts. From to , Dr. Rafield was Managing Director at Apax Partners formerly Patricof amp Co. Ventures , where she was Head of Healthcare responsible for developing a diversified investment strategy for a million healthcare portfolio within a billion fund. While at Apax, she was predominately focused on the creation of therapeutic product companies from pharmaceutical assets and resources, which lead to investments in Zymogenetics Novo Nordisk , Affymax GSK and Aerovance Bayer . From to , Dr. Rafield was an Investment Principal at Robertson Stephens Early Stage Venture Fund. From to , she was an affiliate at Institutional Venture Partners. Dr. Rafield held scientific research and management positions at Somatix Therapy Corp. from to and at Integrated Genetics, Inc. from to , where she directed molecular biology efforts in the development and expression of recombinant proteins. She received a Ph.D. in in Microbiology at University of Virginia Medical School, and was a Postdoctoral Fellow at Harvard Medical School.
  • Karen Drexler / Director
    • Karen Drexler has over years of experience cofounding and building medical device companies, mainly in the diagnostics space. She has served on the Diadexus board of directors since November and chairs the compensation committee. Ms. Drexler previously was president and chief executive officer of Amira Medical, a glucose monitoring company that was sold to Roche in . She is currently an active chairman with Hygieia, a diabetes service company, and is on the board of directors of Naia Health connected devices for growing families and Sandstone Diagnostics point of care and home testing . Ms. Drexler also acts as a senior strategic advisor for several other early stage companies and is on the board of directors for the Keller Center for Innovation in Engineering Education at Princeton University. The holder of issued patents, Ms. Drexler received her MBA from the Graduate School of Business at Stanford University and her BSE in chemical engineering from Princeton University.
  • John Curnutte, M.D., Ph.D / Director
    • Dr. Curnutte has served as a director of the Company since February . Dr. Curnutte has served as executive vice president, research and development since February at Portola Pharmaceuticals, Inc., a biopharmaceutical company developing product candidates for thrombosis and other hematologic diseases. During this time, Portola advanced two innovative thrombosis therapies into pivotal Phase programs and a novel SykJAK kinase inhibitor into the clinic. From April to January , Dr. Curnutte served as an independent consultant. From May to March , Dr. Curnutte served as the Chief Executive Officer of V Biosciences, Inc., a biotechnology company. From September to May , Dr. Curnutte served as president of ScheringPlough Biopharma formerly DNAX Research Institute and now Merck Research Laboratories where he led the drug discovery and early development efforts for biologic therapeutics. During his time with ScheringPlough, eight therapeutic entities progressed into development, including five small molecules and one gene therapy construct, in the immunology and oncology therapeutic areas. Earlier in his career, he held several senior management positions at Genentech, Inc., a biotechnology company, during which he oversaw that Company s immunology discovery program. Prior to Genentech, Dr. Curnutte was a tenured faculty member at The Scripps Research Institute, pursuing basic and clinical research in inflammation biochemistry and the molecular genetics of congenital immune deficiencies. He is currently an adjunct clinical professor of pediatrics at Stanford University School of Medicine and a member of the medical staff, where he continues to consult on patients with primary immunodeficiencies. Dr. Curnutte received an undergraduate degree in biochemistry and molecular biology from Harvard University and an M.D. and a Ph.D. in biological chemistry from Harvard Medical School.
  • Elizabeth Hutt Pollard / Director
    • Elizabeth Hutt Pollard has served as a director of the Company since January . Ms. Hutt Pollard has years of commercial and leadership experience in the life sciences industry. Ms. Hutt Pollard has been a member of the Board of Directors and the Chief Executive Officer of NuGEN Technologies, Inc., or NuGen, a global leader in the development, manufacture and sale of genomic sample preparation products for analysis on leading genetic platforms, such as next generation sequencing systems, since September . She joined NuGEN in as Vice President of Commercial, responsible for establishing NuGEN s brand, portfolio strategy and global sales and technical support infrastructure. Ms. Hutt Pollard moved into the Chief Executive Officer role in September and under her continued leadership, NuGEN has commercialized numerous proprietary products for use in research and diagnostic applications. Prior to joining NuGEN, Ms. Hutt Pollard held commercial management roles with Tripos, Inc., Affymetrix, Inc., and Life Technologies, Inc. during significant growth phases of these businesses. Ms. Hutt Pollard received her M.S. in Business Administration from Central Michigan University and a B.A. in Chemistry from Michigan State University.
  • James Sulat / Director
    • James Sulat has served as a director of the Company since January . Mr. Sulat served as Chair of the Board of Directors for Momenta Pharmaceuticals, Inc., a leader in the analysis, characterization and design of complex pharmaceutical products, since , as the Vice Chair of the Supervisory Board for Valneva SE, a biotech company focusing on vaccines, since , and as a member of the Board of Directors for AMAG Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of specialty pharmaceutical products, since . Previously, Mr. Sulat served as the Chief Executive Officer and Chief Financial Officer of Maxygen, Inc., a biopharmaceutical company, from October to June . Mr. Sulat also served as a member of the Board of Directors of Maxygen, Inc., from October to June . Prior to that, he served as the Chief Financial Officer of Memory Pharmaceuticals Corp., a biopharmaceutical company, from February through September , as Memory Pharmaceuticals Corp. s President and Chief Executive Officer from May through February and as a member of the Board of Directors of Memory Pharmaceuticals Corp. from May through January . Mr. Sulat received a B.S. in Administrative Sciences from Yale University, and an M.B.A. and an M.S. in Health Services Administration from Stanford University.

Current Share Structure

  • Market Cap: $41,001 - 03/20/2018
  • Authorized: 50,000,000 - 07/01/2015
  • Issue and Outstanding: 4,100,060 - 10/29/2015

 


Recent Filings from (OTC: DDXSQ)

Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (OTC: DDXSQ)

Daily Technical Chart for (OTC: DDXSQ)


Stay tuned for daily updates and more on (OTC: DDXSQ)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: DDXSQ)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DDXSQ is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of DDXSQ and does not buy, sell, or trade any shares of DDXSQ. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/